Psychiatric illness, access and adherence to HAART: A brief review of recent findings and implications for care

HIV Therapy

Volumn 4, Issue 2, 2010, Pages 215-230

  Palmer, Nancy B ^b   Basinski, James R ^a   Uldall, Karina K ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Access; Adherence; HAART; HIV; Interventions; Mental illness; Psychiatric illness

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; SEROTONIN UPTAKE INHIBITOR;

ANXIETY DISORDER; CLINICAL RESEARCH; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; MENTAL DISEASE; MENTAL HEALTH; MENTAL HEALTH SERVICE; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PSYCHIATRIC DIAGNOSIS; REVIEW; SUBSTANCE ABUSE;

EID: 77951693225     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.10.4     Document Type: Review

References (45)

1. Karon JM, Fleming PL, Steketee RW, De Cock KM: HIV in the United States at the turn of the century: an epidemic in transition. Am. J. Public Health 91 (7), 1060-1068 (2001).
2. Lima VD, Hoggs RS, Harrigan PR et al.: Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21 (6), 685-692 (2007).
3. Murphy EL, Collier AC, Kalish LA et al.: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135 (1), 17-26 (2001).
4. Paterson DL, Swindells S, Mohr, J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133 (1), 21-30 (2000).
5. Nieuwkerk PT, Sprangers MA, Burger DM et al.: Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study Arch. Intern. Med. 161 (16), 1962-1968 (2001).
6. Condra JH, Schleif WA, Blahy OM et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374 (6522), 569-571 (1995).
7. Ammassari A, Trotta MP, Murri R et al.: Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J. Acquir. Immune Defic. Syndr. 31 (Suppl. 3), S123-S127 (2002).
8. Chesney M: Adherence to HAART regimens. AIDS Patient Care STDS 17 (4), 169-177 (2003).
9. Chander G, Himelhoch S, Moore RD: Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs 66 (6), 769-789 (2006).
10. Uldall KK, Palmer NB, Whetten K, Mellins C; HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study Group: Adherence in people living with HIV/AIDS, mental illness and chemical dependency: a review of the literature. AIDS Care 16 (Suppl. 1), S71-S96 (2004).
11. Chander G, Himelhoch S, Fleishman JA et al.: HAART receipt and viral suppression among HIV-infected patients with cooccurring mental illness and illicit drug use. AIDS Care 21 (5), 655-663 (2009).
12. Mellins CA, Havens JF, McDonnell C et al.: Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders. AIDS Care 21 (2), 168-177 (2009).
13. Chesney MA, Ickovics JR, Chambers DB et al.: Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care 12 (3), 255-266 (2000).
14. HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study Group: The HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study: conceptual foundations and overview. AIDS Care 16 (Suppl. 1), S6-S21 (2004).
15. Atkinson JS, Schonnesson LN, Williams ML, Timpson SC: Associations among correlates of schedule adherence to antiretroviral therapy (ART) : a path analysis of a sample of crack cocaine using sexually active African-Americans with HIV infection. AIDS Care 20 (2), 253-262 (2008).
16. Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM: The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS 22 (3), 233-243 (2008).
17. Pence BW, Miller WC, Gaynes BN, Eron JJ Jr: Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy J. Acquir. Immune Defic. Syndr. 44 (2), 159-166 (2007).
18. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J; Adolescent Trials Network for HIV/AIDS Interventions: Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDS23 (3), 1-10 (2009).
19. Walkup J, Akincigil A, Bilder S, Rosato NS, Stephen C: Psychiatric diagnosis and antiretroviral adherence among adolescent Medicaid beneficiaries diagnosed with human immunodeficiency virus/acquired immunodeficiency syndrome. J. New, Ment. Dis. 197 (5), 354-361 (2009).
20. Bogart LM, Fremont AM, Young AS et al.: Patterns of HIV care for patients with serious mental illness. AIDS Patient Care STDS 20 (3), 175-182 (2006).
21. Himelhoch S, Brown CH, Walkup J et al.: HIV patients with psychiatric disorders are less likely to discontinue HAART. AIDS 23, 1735-1742 (2009).
22. Himelhoch S, Chander G, Fleishman JA, Hellinger J, Gaist P, Gebo KA: Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use. Gen. Hosp. Psychiatry 29 (6), 518-525 (2007).
23. Lima VD, Geller J, Bangsberg DR et al.: The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART AIDS 21 (9), 1175-1183 (2007).
24. Berger-Greenstein JA, Cuevas CA, Brady SM, Trezza G, Richardson MA, Keane TM: Major depression in patients with HIV/AIDS and substance abuse. AIDS Patient Care STDS 21 (12), 942-955 (2007).
25. Horberg MA, Silverberg MJ, Hurley LB et al.: Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 47 (3), 384-390 (2008).
26. Walkup J, Wei W, Sambamoorthi U, Crystal S: Antidepressant treatment and adherence to combination antiretroviral therapy among patients with AIDS and diagnosed depression. Psychiatr. Q. 79 (1), 43-53 (2008).
27. Cook JA, Grey DD, Burke-Miller JK et al.: Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-ske cohort of HIV-positive women. AIDS Care 18 (2), 93-100 (2006).
28. Cook JA, Grey DD, Burke-Miller JK et al.: Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend. 89 (1), 74-81 (2007).
29. Kapadia F, Vlahov D, Wu Y et al.: Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am. J. Drug Alcohol Abuse 3 A (2), 161-170 (2008).
30. Boarts JM, Sledjeski EM, Bogart LM, Delahanty DL: The differential impact of PTSD and depression on HIV disease markers and adherence to HAART in people living with HIV. AIDS Behav. 20 (2), 253-262 (2006).
31. Vranceanu AM, Safren SA, Lu M et al.: The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV AIDS Patient Care STDS 22 (4), 313-321 (2008).
32. Mugavero M, Ostermann J, Whetten K et al.: Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS 20 (6), 418-428 (2006).
33. Carrico AW, Johnson MO, Moskowitz JT et al.: Affect regulation, stimulant use, and viral load among HIV-positive persons on anti-retroviral therapy Psychosom. Med. 69 (8), 785-792 (2007).
34. Carrico AW, Johnson MO, Colfax GN, Moskowitz JT: Affective correlates of stimulant use and adherence to anti-retroviral therapy among HIV-positive methamphetamine users. AIDS Behav. (2009) DOI:10.1007/sl046l-008-9513-y (Epub ahead of print).
35. Parsons JT, Rosof E, Mustanski B: Patient-related factors predicting HIV medication adherence among men and women with alcohol problems. J. Health Psychol. 12 (2), 357-370 (2007).
36. Reinhard MJ, Hinkin CH, Barclay TR et al.: Discrepancies between self-report and objective measures for stimulant drug use in HIV: cognitive, medication adherence and psychological correlates. Addict. Behav. 32, 2727-2736 (2007).
37. Barclay TR, Hinkin CH, Castellon SA et al.: Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognkive status. Health Psychol. 26 (1), 40-49 (2007).
38. Ettenhofer ML, Hinkin CH, Castellon SA et al.: Aging, neurocognkion, and medication adherence in HIV infection. Am. J. Geriatr. Psychiatry 17 (4), 281-290 (2009).
39. Woods SP, Moran LM, Carey CL et al.: Prospective memory in HIV infection: is "remembering to remember" a unique predictor of self-reported medication management? Arch. Clin. Neuropsychology 23, 257-270 (2008).
40. Woods SP, Dawson MS, Weber E, Gibson S, Grant I, Atkinson JH; HIV Neurobehavioral Research Center Group: Timing is everything: antiretroviral nonadherence is associated with impairment in time-based prospective memory J. Int. Neuropsychol. Soc. 15 (1), 42-52 (2009).
41. Gorman AA, Foley JM, Ettenhofer ML, Hinkin CH, van Gorp WG: Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol. Rev. 19, 186-203 (2009).
42. Balfour L, Kowal J, Silverman A et al.: A randomized controlled psycho-education intervention trial: improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART. AIDS Care 18 (7), 830-838 (2006).
43. Safren SA, O'Cleirigh C, Tan JY et al.: A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 28 (1), 1-10 (2009).
44. Simoni JM, Pantalone DW, Plummer MD, Huang B: A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women. Health Psychol. 26 (4), 488-495 (2007).
45. Whetten K, Reif S, Ostermann J et al.: Improving health outcomes among individuals with HIV, mental illness, and substance use disorders in the Southeast. AIDS Care 18 (Suppl. 1), S18-S26 (2006).